STI Stock Trade Intelligence
AVE

AVECHO BIOTECHNOLOGY LIMITED

Health Care · ASX:AVE
$0.0120
▲ +20.00%
Market cap
$46M
Turnover
$135,645
Last price
$0.0120
Day change
+20.00%
Announcements
14
Range, past year
Open 0.006 · Low 0.003 · Now 0.012 · High 0.027
Open AVE in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

AVE momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
29/100
Wyckoff phase
Accumulation1d
Trend stage
Neutral
1 Day
+20.0%
1 Week
+0.0%
1 Month
-14.3%
1 Year
+100.0%
RSI
43
Avg daily range
14.2%

AVECHO BIOTECHNOLOGY LIMITED scores 29 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 1 trading day. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.90 — highly linear uptrend
Points to watch
  • 60d drawdown -60.0%
  • High volatility (ATR 14.2%)
  • Risk rating: Very High
  • Composite downside risk elevated
AVE appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

AVE announcements

Recent price-sensitive releases.
  • 2026-10-28 September 2026 Quarterly Activities Report & Appendix 4C Commitments Test Entity - Third Quarter Activity Report | Commitments Test Entity - Third Quarter Cashflow Report
  • 2026-10-21 Response to ASX Price Query Response to ASX Query
  • 2026-08-31 Avecho enters final stage of Phase III insomnia trial Progress Report
  • 2026-08-26 Appendix 4D and Half-year Financial Report Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report
  • 2026-07-29 June 2026 Quarterly Activities Report & Appendix 4C Commitments Test Entity - Second Quarter Activity Report | Commitments Test Entity - Second Quarter Cashflow Report
  • 2026-06-24 Positive interim results from Phase III insomnia program
  • 2026-06-22 Trading Halt
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.